Immunome, Inc.
IMNM
$8.49
$0.030.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 6.87% | -5.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.87% | -5.91% | |||
| Cost of Revenue | -23.01% | 28.74% | |||
| Gross Profit | 24.82% | -31.68% | |||
| SG&A Expenses | 2.34% | 9.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.47% | 24.85% | |||
| Operating Income | 19.72% | -26.89% | |||
| Income Before Tax | 48.11% | -70.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 48.11% | -70.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.11% | -70.38% | |||
| EBIT | 19.72% | -26.89% | |||
| EBITDA | 20.17% | -27.05% | |||
| EPS Basic | 58.94% | -63.25% | |||
| Normalized Basic EPS | 37.69% | -25.42% | |||
| EPS Diluted | 59.06% | -63.72% | |||
| Normalized Diluted EPS | 37.69% | -25.42% | |||
| Average Basic Shares Outstanding | 26.37% | 4.37% | |||
| Average Diluted Shares Outstanding | 26.37% | 4.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||